Tralokinumab Treatment in Adult Atopic Dermatitis Patients: 28-Week Evaluation of Clinical Effectiveness, Safety, Serum Proteins and Total IgE Levels

    December 2024 in “ Allergy ”
    Coco Dekkers, Nicolaas P. A. Zuithoff, Daphne S. Bakker, Edward F. Knol, Anne F. J. Wevers, Wouter Touwslager, Wianda A. Christoffers, Petra Prosje, Anneke van Lynden‐van Nes, Paula van Lümig, Marijke Kamsteeg, Albert J. Oosting, Marie L. A. Schuttelaar, Inge Haeck, Marlies de Graaf, Femke van Wijk, Marjolein de Bruin‐Weller
    This study evaluated the 28-week effectiveness and safety of tralokinumab in 84 adult patients with moderate-to-severe atopic dermatitis (AD). The treatment significantly improved clinical outcomes, with 75.8% achieving an Eczema Area and Severity Index (EASI) of ≤7 and 51.4% achieving a numerical rating scale (NRS) for pruritus of ≤4. Serum proteins associated with disease severity decreased, and total IgE levels significantly decreased in dupilumab-naïve patients. However, 27.4% of patients discontinued treatment due to adverse events or ineffectiveness, with hair loss being the most common reason for discontinuation. Overall, tralokinumab proved effective for both dupilumab-naïve and non-naïve patients, with clinical improvements supported by biological data.
    Discuss this study in the Community →